单唾液酸四己糖神经节苷脂钠治疗糖尿病周围神经病变临床疗效观察

The study of GM1 treatment on diabetic peripheral neuropathy

目的探讨单唾液酸四己糖神经节苷脂钠(GM1)治疗糖尿病周围神经病变临床应用前景。方法将56例糖尿病周围神经病变患者随机分为GM1治疗组和甲钴胺治疗组,两组均给予常规降糖、改善循环等治疗,3个月后观察治疗前后临床症状改善情况并测定治疗前后患者血清一氧化氮(NO)水平。结果①GM1组治疗有效率高于甲钴胺组,但差异无统计学意义,(P>0.05);②治疗前两组NO水平差异无统计学意义,治疗后两组自身比较,差异有统计学意义(P<0.001),且治疗后GM1组明显高于甲钴胺组(P<0.001)。结论 GM1治疗糖尿病周围神经病变有良好前景,待进一步观察。

Objective To study the clinical use perspective of GM1 in the treatment of diabetic peripheral neuropathy （DPN） ;Methods Fifty-six patients with diabetic peripheral neuropathy were subjected to GMI group and mecobalamine group randomly and treated with normal therapy such as anti - hyperglycaemia, restore circulation profile and et cetera. After three months at the end of our test we evaluated their clinical symptom improvement and tested their serum levels of nitrogen monoxidum （NO） before and after the study. Results ①The effective power percentile of GMI group was higher than that of the mecobalamine group but without a statistic difference（ P 〉 0.05）. ②We found no statistic difference of NO levels between the two groups before our study, but there was significantly inerease of NO after 3 months treatment respectively and the NO level of GM1 group was even higher than that of the mecobalamine group at the end （P 〈0. 001 ）. Conclusion GMI has potential perspective in the treatment of diabetic peripheral neuropathy and need further observation.